Cancer Immunotherapies: What the Perioperative Physician Needs to Know.
Curr Oncol Rep
; 24(4): 399-414, 2022 04.
Article
en En
| MEDLINE
| ID: mdl-35141856
ABSTRACT
PURPOSE OF REVIEW For patients with cancer, treatment may include combination therapy, including surgery and immunotherapy. Here, we review perioperative considerations for the patient prescribed immunotherapeutic agents. RECENT FINDINGS:
The perioperative period is a poignant moment in the journey of a patient with cancer, potentially deemed most influential compared to other moments in the care continuum. Several immunotherapeutic medications have been employed near the time of surgery to potentially increase effectiveness. Of the various drug classes, including immune checkpoint inhibitors, cytokines, toll-like receptor agonists, and oncolytic viruses, among others, several notable immune-related adverse effects were noted. They range from minor effects to more serious ones, such as renal failure, myocarditis, and tumor growth. Surgery and immunotherapy are often employed in combination for primary treatment and prevention of cancer recurrence. Careful review and consideration of the pharmacokinetics, pharmacodynamics, and toxicities of immunotherapy benefit the perioperative physician and their patients.Palabras clave
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Médicos
/
Viroterapia Oncolítica
/
Neoplasias
Límite:
Humans
Idioma:
En
Año:
2022
Tipo del documento:
Article